Seeds of Life, 100 New Beginnings: GoBroad Shanghai Zhaxin & Liquan Hospitals Reach 100 Unrelated HSCTs

Summary: In June 2026, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital completed their 100th unrelated hematopoietic stem cell transplant. Both are designated transplant hospitals within the China Marrow Donor Program (CMDP). Led by Dr. Chun WANG, the hospitals have completed more than 900 hematopoietic stem cell transplants over the past six years. This article explains the carefully coordinated process of an unrelated-donor search, from HLA matching and donor confirmation to stem cell collection, transport, infusion, and follow-up. It also highlights why unrelated donors can be especially important when a suitable family donor is unavailable. To date, 80 healthcare professionals from the hospitals have also registered with the CMDP as potential donors.

What can a one-in-100,000 chance mean? Somewhere among millions of people, two strangers can become connected by a single bag of hematopoietic stem cells - a true "seed of life."

In June 2026, in the transplant ward at GoBroad Shanghai Zhaxin Hospital, hematopoietic stem cells carrying the hope of a new beginning were infused into a patient with severe aplastic anemia. The cells came from an unrelated donor she had never met. After a full matching process coordinated through the China Marrow Donor Program (CMDP), the donation traveled across the country and finally reached her bedside, bringing a new possibility for recovery.

This was the hospitals' 100th unrelated hematopoietic stem cell transplant.

From the first case to the 100th, and from 355 donor searches to 100 successful infusions, every number represents far more than a clinical milestone. Behind it are volunteer donors, coordinators, clinicians, nurses, laboratory professionals, and many others working together to give patients another chance.

GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital are comprehensive hospitals with a strong focus on hematologic diseases, and both are designated hematopoietic stem cell collection and transplant hospitals within the China Marrow Donor Program. Over the past six years, the transplant program has been led by Dr. Chun WANG, former Director of the Department of Hematology at Shanghai General Hospital. Together with a core multidisciplinary team with extensive tertiary-hospital experience, the hospitals have made hematopoietic stem cell transplantation a key part of care for complex and high-risk blood disorders. To date, they have completed more than 900 hematopoietic stem cell transplants, including unrelated-donor procedures, across a wide range of complex hematologic conditions. The hospitals have also developed an integrated care system spanning transplantation, cellular therapy, post-transplant management, multidisciplinary care, and specialized nursing.

Within those more than 900 transplants, the 100th unrelated-donor transplant marks a particularly meaningful milestone.

01 What Is an Unrelated Donor Search? A Carefully Coordinated Path from Match to Transplant

An unrelated donor search is a tightly coordinated process involving authorized transplant hospitals and the China Marrow Donor Program. Hospitals that participate in the CMDP network must meet defined qualification requirements and have dedicated coordinators who stay in close contact with the registry. The process can include searching for a potential unrelated donor, confirming HLA compatibility, coordinating stem cell collection, arranging safe transport to the transplant center, completing the transplant, and supporting long-term follow-up. Each step depends on careful communication, timing, and quality control.

Finding a fully HLA-matched unrelated donor can still be challenging because human leukocyte antigen (HLA) types are highly diverse. The source article cites the chance of finding a fully matched unrelated donor as approximately one in 100,000. For a patient and donor who have never met, that rare match can create a life-changing connection.

 02 When a Family Donor Is Not Available, an Unrelated Donor May Open Another Path

Finding a suitable donor has long been one of the biggest challenges in hematopoietic stem cell transplantation. Today, advances in haploidentical transplantation mean that donor options are no longer limited to fully matched relatives. However, some patients still cannot use a family donor - for example, an only child without siblings, or a family in which inherited genetic abnormalities make a related donor unsuitable. In these situations, an unrelated donor may become an especially important, and sometimes the only feasible, transplant option.

The China Marrow Donor Program continues to expand. The source article reports a registry of more than 3.78 million potential donors. Each person who registers creates another possibility for a patient in need. Combined with advances in modern transplantation, unrelated-donor transplantation can offer an important treatment pathway for patients who otherwise have limited donor options.

03 Beyond Clinical Care: A Commitment to Donation and Social Responsibility

Since their establishment, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital have incorporated social responsibility into their medical mission. The hospitals regularly organize voluntary blood-donation activities and hematopoietic stem cell donor-registration drives.

To date, 80 healthcare professionals from the hospitals have provided blood samples and formally registered with the China Marrow Donor Program as potential donors. In May 2023, a hematologist from GoBroad Shanghai Zhaxin Hospital went one step further and donated hematopoietic stem cells to a patient they had never met. This act of generosity reflects GoBroad's patient-centered philosophy: "The Needs of the Patient Come First."

The 100th Transplant Is a Milestone - and a New Starting Point

Reaching 100 unrelated-donor transplants would not have been possible without close coordination at every stage. We extend our sincere appreciation to the professionals of the China Marrow Donor Program, every volunteer unrelated donor, and all those involved in transport, coordination, laboratory testing, nursing, and other behind-the-scenes work. Every contribution has helped make transplantation possible for patients and families facing serious blood disorders.

As they move forward from this 100-case milestone, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital will continue to work closely with the China Marrow Donor Program and partners across the community. Guided by the principle that "The Needs of the Patient Come First," the hospitals will continue strengthening transplant care while bringing compassionate support to more patients with hematologic diseases.

From the first unrelated-donor transplant to the 100th, and from zero to more than 900 hematopoietic stem cell transplants overall, GoBroad Shanghai Zhaxin Hospital and GoBroad Shanghai Liquan Hospital continue to build experience in caring for patients with complex blood disorders - combining clinical expertise with long-term, patient-centered care.